Ken Griffin's position in Sarepta Therapeutics is currently worth $107 Million. That's 0.13% of their equity portfolio (191st largest holding). The first Sarepta Therapeutics trade was made in Q2 2013. Since then Ken Griffin bought shares 48 more times and sold shares on 43 occasions. The stake costed the investor $56.7 Million, netting the investor a gain of 89% so far.